In the normal liver, almost all cells are in a resting G0 phase with little turnover and virtually no cell death 1, 2 . This state becomes perturbed in chronic liver dis ease (CLD), in which viral, toxic, metabolic or auto immune injuries induce hepatocellular death, followed by inflammation and compensatory hepatocyte pro liferation 3 . Although these responses ensure efficient regeneration in the setting of acute hepatocellular injury, chronic hepatocyte death and the associated inflammation have been closely linked to the develop ment of fibrosis, cirrhosis and hepatocellular carcinoma (HCC) 3 . Accordingly, HCC almost exclusively develops in patients with CLD, whereas cancer in many other organs such as the colon, pancreas, kidney and brain often develops spontaneously in the absence of chronic injury or disease 4 . In contrast to most other organs, the liver possesses a profound ability to regenerate -full liver mass following twothirds partial hepatectomy is restored within 7-10 days, reflecting the essential role of the liver in many vital processes 1 . However, there are only minor changes in the synthetic function of the liver in the early stages of CLD, as evidenced by normal levels of serum albumin and clotting factors as well as by cholesterol and bile acid metabolism and the lack of clinical symptoms 5 . On the one hand, this reflects the functional reserve of the liver; on the other, it seems that the prototypical response of the liver towards cell death is geared towards the threat of acute liver failure and that there is no or only insufficient finetuning of cell death responses when injury becomes chronic in CLD. Accordingly, the wound healing responses in CLD have been characterized as maladaptive 3 , increasing the risk of disease progression and cancer in the long run.
Whereas evidence from clinical studies and animal models has clearly established the strong association of hepatocyte death with key complications of CLDthat is, fibrosis, cirrhosis and HCC development -we are only beginning to understand mechanisms through which cell death in the liver contributes to these complica tions. In the past decade, it has become apparent that cell death comes in many flavours and that different modes of cell death can be activated in disease, triggering distinct responses and biological outcomes [6] [7] [8] [9] [10] . As such: physio logical cell death during development and organ turnover is ideally nonreactive in terms of compensatory regen eration and immune cell activation 11 ; toxic and/or mas sive cell death should trigger regenerative responses 10, 12 ; and cell death induced by pathogens ideally eliminates patho gens and elicits immune responses 13 . Besides necro sis and apoptosis as wellestablished forms of cell death, several new modes of cell death have been discovered and characterized in the past decade, including necroptosis, pyroptosis and ferroptosis 8, 9, 14 . Hence, it is conceivable that specific modes of cell death are tailored for distinct Apoptosis and necroptosis in the liver: a matter of life and death Robert F. Schwabe 1, 2 * and Tom Luedde 3 * Abstract | Cell death represents a basic biological paradigm that governs outcomes and long-term sequelae in almost every hepatic disease condition. Acute liver failure is characterized by massive loss of parenchymal cells but is usually followed by restitution ad integrum. By contrast, cell death in chronic liver diseases often occurs at a lesser extent but leads to long-term alterations in organ architecture and function, contributing to chronic hepatocyte turnover, the recruitment of immune cells and activation of hepatic stellate cells. These chronic cell death responses contribute to the development of liver fibrosis, cirrhosis and cancer. It has become evident that, besides apoptosis, necroptosis is a highly relevant form of programmed cell death in the liver. Differential activation of specific forms of programmed cell death might not only affect outcomes in liver diseases but also offer novel opportunities for therapeutic intervention. Here, we summarize the underlying molecular mechanisms and open questions about disease-specific activation and roles of programmed cell death forms, their contribution to response signatures and their detection. We focus on the role of apoptosis and necroptosis in acute liver injury , nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and liver cancer, and possible translations into clinical applications.
settings. Importantly, different modes of cell death might endow us with new opportunities to therapeutically modify the course of CLD, either by directly interfering with mediators that regulate each form of cell death or with mediators that promote responses to specific types of cell death. In this Review, we focus on apoptosis and necroptosis, the current knowledge on their interplay and connections to cell death responses and their roles in murine models of liver disease and in patients. Given the rapid expansion of knowledge on each form of cell death, we focus on the distinct functions of apoptosis and necroptosis in liver disease to enable sufficiently deep insight. Pyroptosis, ferroptosis and autophagic cell death represent alternative forms of programmed cell death that might prove equally important in liver disease as apoptosis or necroptosis. However, despite promising data from studies published in the past few years [15] [16] [17] , the overall experimental evidence for their potential function in liver injury and carcinogenesis seems to be less advanced, and so we refer the reader to excellent reviews on these pathways 8, 9, [18] [19] [20] .
Principles of apoptosis and necroptosis
Cell death can occur in distinct pathophysiological con texts. In the setting of massive hypoxic or toxic injury, cells can reach a state of cellular stress and energy deple tion in which they lose their ability to maintain basic homeostatic functions, resulting in necrosis, a passive and uncontrolled autolytic loss of cellular integrity 21 . Morphologically, cells undergoing necrosis typically show a swelling and disruption of cell membranes and organelles without the pyknosis (a reduction of cellular and nuclear volume) seen upon chromatin condensation in apoptosis 22 . In the liver, necrosis is observed in multi ple disease contexts and experimental models, such as ischaemia-reperfusion injury or acute liver injury owing to carbon tetrachloride (CCl 4 ) treatment or acetaminophen (also known as paracetamol) intoxication 23 . Moreover, necrosis is believed to trigger a massive inflammatory response that can cause substantial collateral damage to neighbouring cells 24 . In contrast to the passive necrosis that results from detrimental injury or stress, cell death can also be executed in an ordered, regulated fashion via a specific cell suicide programme termed apoptosis, which exerts only minimal effects on surrounding cells and thereby does not disrupt tissue homeostasis or organ development. For years, the term apoptosis was used syn onymously with the term programmed cell death, until it became evident that additional forms of programmed cell death existed. Morphologically, apoptosis is characterized by cellular shrinkage, a dense cytoplasm with tightly packed organelles and pyknosis caused by the character istic condensation and fragmentation of chromatin 22 . The biochemical execution of apoptosis is mediated by the activation of initiator and executioner caspases, which kill cells through the cleavage of proteins and subse quent activation of nucleases that cleave DNA into short, regularly sized fragments 25 .
Regulation of apoptosis and necroptosis
As the execution of apoptosis is considered an irre versible process, whereby caspase activation com mits a cell to death, the activation of the apoptotic machinery is a tightly regulated process. Caspase acti vation can be either mediated through the intrinsic, mitochondrialdependent pathway 25 or through the extrinsic, death receptordependent pathway that is triggered, for example, through TNF signalling or acti vation of apoptosismediating surface antigen FAS by FAS antigen ligand (FASL) 26 . Whereas FAS activation triggers death in many cell types, TNF simultaneously activates proapoptotic and antiapoptotic signals, and cells die only if antiapoptotic signals, mostly mediated by nuclear factorκB (NFκB) activation, are suppressed 27 ( Fig. 1) . Binding of TNF to its receptor, TNF receptor 1 (TNFR1), induces the transient formation of a primary membranebound signalling complex known as TNFR1 complex I, which mediates the expression of prosurvival genes such as those encoding cellular FLICElike inhib itory protein (cFLIP; also known as CFLAR), apop tosis regulator BCLX L (also known as BCL2L1) or E3 ubiquitinprotein ligase XIAP 28 . As part of complex I, the adaptor proteins TNFRSF1Aassociated via death domain (TRADD) and receptorinteracting serine/ threonineprotein kinase 1 (RIPK1) are recruited to the receptor, serving as platforms for the recruitment of vari ous other proteins including TNF receptorassociated factor 2 (TRAF2) and members of the inhibitor of apoptosis protein (IAP) family, such as cellular inhibi tor of apoptosis 1 (CIAP1; also known as BIRC2) and CIAP2 (also known as BIRC3). Through complex ubiqui tylation events involving the generation of K63linked, K11linked, K48linked and linear ubiquitin chains, the TAK1binding protein 2 (TAB2) and/or TAB3-TAB1-orphan nuclear receptor TAK1 (also known as NR2C2) complex and the inhibitor of NFκB (IκB) kinase (IKK) complex (consisting of the kinases IKK subunitα (IKKα), IKKβ and the regulatory subunit NFκB essential modulator (NEMO)) are recruited to complex I (Fig. 1) . In many cell types, the kinase TAK1 activates mitogenactivated protein kinases (MAPKs) such as JUN Nterminal kinase (JNK), extracellularsignalregulated kinase (ERK) and p38 MAPK, but experiments in Tak1 (also known as
Key points
• Cell death is a fundamental driver of liver disease progression to liver fibrosis, cirrhosis and hepatocellular carcinoma.
• Depending on the underlying disease entity, distinct forms of programmed cell death and cell death response pathways can be activated in the liver.
• Necroptosis is a new form of programmed cell death that is activated by the necrosome, which consists of the kinases receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and RIPK3 and the pseudokinase mixed lineage kinase domain-like protein (MlKl).
• Despite necroptosis being challenging to detect in vivo, there is accumulating evidence that this cell death form is a pathogenically relevant driver in several liver diseases that were associated with apoptosis.
• Necroptosis seems to be particularly important in nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and liver cancer but does not contribute to acetaminophen toxicity or ischaemia-reperfusion injury.
• A better functional characterization of necroptosis in liver disease models might lead to novel therapeutic strategies that target necroptosis to prevent the progression and decompensation of chronic liver disease.
Nr2c2)deficient liver cells showed that their activation in hepatocytes can be mediated independently of TAK1
(reF.
29,30
). However, TAK1 is absolutely essential for IKKβ phosphorylation 29 , which drives ubiquitylation and pro teasomal degradation of the inhibitory protein IκBα (also known as NFKBIA), thereby allowing NFκB dimers consisting of the nuclear factor NFκB subunits p50 and p65 to translocate to the nucleus and drive the transcrip tion of NFκBdependent genes such as those encoding cFLIP, CIAPs or zincfinger protein A20 (also known as TNFαinduced protein 3).
Defective activation of NFκB (for instance, through genetic deletion of Nemo (also known as Ikbkg) 31, 32 or Rela (which encodes p65)) 33 switches cellular TNF responses from survival towards cell death by the for mation of a caspase 8activating complex called com plex II (Fig. 1 Activation of distinct cell death pathways in response to TNF signalling is regulated by diverse post-transcriptional modification steps, including phosphorylation and ubiquitylation. Upon ligation of TNF to its receptor, TNF receptor 1 (TNFR1), distinct signalling complexes can be formed, which is mainly orchestrated through ubiquitylation events that influence cell fate towards survival or cell death. The first complex that forms upon TNF stimulation is complex I, consisting of the adaptor protein TNFRSF1A-associated via death domain (TRADD), receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and the E3 ligases TNF receptor-associated factor 2 (TRAF2), cellular inhibitor of apoptosis 1 (CIAP1) and CIAP2, which together mediate the main ubiquitylation events (for example, ubiquitylation of K63 and K48), thereby enabling the further recruitment of the linear ubiquitin chain assembly complex (LUBAC), the inhibitor of NF-κB (IκB) kinase (IKK) complex (comprising IKK subunit-α (IKKα), IKKβ and NF-κB essential modulator (NEMO)), orphan nuclear receptor TAK1 and its adaptor proteins (TAK1-binding protein 1 (TAB1), TAB2 and TAB3) and subsequent activation of the pro-survival transcription factor nuclear factor-κB (NF-κB). Upon genetic or pharmacological inactivation of NF-κB or other factors that drive NF-κB activation (such as TAK1 or NEMO), deubiquitylation and release of RIPK1 from complex I can promote the formation of other complexes that tip the balance of TNF signalling towards cell death. Complexes containing FAS-associated death domain protein (FADD), caspase 8 and RIPK1 (complex IIb) or alternatively TRADD (complex IIa) typically trigger apoptosis. By contrast, complexes containing RIPK1 and RIPK3 (complex IIc) typically activate necroptosis, a form of programmed necrosis, via RIPK3-mediated phosphorylation of mixed lineage kinase domain-like protein (MLKL). Complex formation is further modified by deubiquitinases such as zinc-finger protein A20, ubiquitin carboxyl-terminal hydrolase CYLD or ubiquitin carboxyl-terminal hydrolase 2. c-FLIP, cellular FLICE-like inhibitory protein; p50, nuclear factor NF-κB subunit p50; p65, nuclear factor NF-κB subunit p65.
www.nature.com/nrgastro dependent on the kinase activity of RIPK1 and mediates apoptosis independently of NFκB target genes. RIPK1 dependent apoptosis in hepatocytes can be specifically activated through combined deletion of IKKα and IKKβ because these kinases directly phosphorylate RIPK1 at several serine residues (for example, S330 and S331) 36 , thereby preventing the autoactivation of RIPK1 dependent cell death in an NFκBindependent fash ion. Finally, beyond its proapoptotic role, RIPK1 has a kinaseindependent antiapoptotic function in hepato cytes facilitated by the prevention of ubi quitylation and degradation of the survival molecule TRAF2 (reFs 37, 38 ).
For many years, the term apoptosis was used synony mously with programmed cell death, whereas necrosis was considered a purely accidental, nonregulated form of cell death. However, it has long been known that TNF can induce both apoptosis and cell death with features of necrosis 39 . In 1998, the group of Peter Vandenabeele showed that inhibition of caspases triggered a controlled form of necrosis in fibrosarcoma cells 40 . This new form of necrosis -similar to complex IIbdependent apoptosis -was subsequently shown to depend on RIPK1 and was named necroptosis 41, 42 . Finally, in 2009 and 2010, several groups showed that the kinase RIPK3 and the pseudokinase mixed lineage kinase domainlike protein (MLKL) are additional key mediators of necroptosis [43] [44] [45] [46] . In this pathway, activation of RIPK1 and parallel inhibi tion of caspase 8 promote a shift from RIPK1induced apoptosis (complex IIb) towards necroptosis, which is mediated by the necrosome, a complex containing RIPK1, RIPK3 and MLKL (Fig. 1) . After phosphorylation of MLKL by RIPK3, phosphorylated MLKL undergoes a conforma tional change and oligomerizes, after which it binds to lipids in the plasma membrane. This binding is sufficient to perforate membrane structures and execute cell lysis 47 .
Functions of apoptosis and necroptosis
Cell death occurs in many settings, including develop ment, homeostasis, chemical, physical or hypoxic injury and cancer. The existence of multiple forms of cell death provides not only the ability to kill cells by the most appropriate method for a specific context but also serves as a backup mechanism in settings in which specific types of cell death fail or are actively evaded. Caspase 8 not only is an important part in the execution of apop tosis but also represents a central switch that directs cells towards specific types of cell death: activation of caspase 8 promotes apoptosis, whereas suppression of caspase 8 activity shifts the balance towards necroptosis 7 . Vice versa, it has been suggested that activity of RIPK3 determines the execution of apoptosis, with catalytically inactive RIPK3 promoting apoptosis 48 . Thus, apoptosis and necroptosis seem to regulate each other reciprocally.
As a number of pathogens or tumour cells have the ability to suppress caspase activity, necroptotic cell death has been proposed to serve as a backup system that enables the killing of infected or malignant cells. This hypo thesis is consistent with a central role of these two forms of programmed cell death as defence mechanisms against infections 13 . Although the presence of a backup programmed cell death mechanism might be advanta geous in specific settings such as viral infection or can cer, the suppression of necroptosis by caspase 8 activity is also an important feature of the healthy state. Accordingly, loss of caspase 8 during development is detrimental and leads to embryonic lethality between embryonic days 10.5 and 11.5. This phenotype has been ascribed to a lack of necroptosis suppression rather than an inability to kill cells via apoptosis 49 . As many proapoptotic stimuli such as TNF can also engage necroptosis and as these two types of cell death regulate each other, further research is needed to define their relative roles in disease settings besides viral infection. The noninflammatory nature of apoptosis in most settings probably results from the lack of cellular leakage and the rapid clearance of apoptotic cells or bodies by phagocytic cells via specific 'find me' and 'eat me' signals (discussed later) [50] [51] [52] . By contrast, necroptotic death is mediated by the rupture of the plasma membrane and release of cellular contents, which presum ably triggers substantial inflammation 53 . Thus, one of the largest differences between apoptosis and necroptosis is the ensuing response to cell death, which often dictates the longterm outcome in patients with liver disease. Despite this clear distinction between inflammatory necroptosis and noninflammatory apoptosis, apoptotic cells can trigger inflammation in specific settings, possibly owing to secondary necrosis, particularly when apoptotic cells escape efferocytosis (the process by which dead cells are removed by phagocytic cells) 50 . Evasion of efferocyto sis might promote inflammation through not only sec ondary necrosis but also the lack of antiinflammatory signals in phagocytic cells triggered by efferocytosis 54 . Likewise, decreasing ATP levels in hepatocytes might make it impossible to maintain energyconsuming apop tosis and result in conversion to secondary necrosis 23, 55 . However, this effect is more likely to be seen in vitro, where apoptotic cells are not eliminated by efferocytosis when cultured and killed in the absence of phagocytic cells. Substantial secondary necrosis in vivo is more likely to occur when efferocytosis is either inhibited or overwhelmed (such as in livers of mice with conditional deletion of Tak1) 30 .
Responses to apoptosis and necroptosis
Whereas the recognition of nonself antigens is the prin cipal driver of the adaptive immune system, conserved molecular patterns activate innate immune responses via specific pattern recognition receptors (PRRs). The 'dan ger theory' proposes that the innate immune system recog nizes not only foreign molecular patterns but all forms of danger, in particular, cell damage and cell death 56 . In this theory, apoptotic cell death results in a lower degree of inflammation than necroptotic cell death, mostly owing to the rapid clearance of apoptotic cells via specific 'find me' and 'eat me' signals 51, 52 but possibly also by caspase 8mediated suppression of the NACHT, LRR and PYD domainscontaining protein 3 (NLRP3) inflammasome 57 . Moreover, apoptotic cells might also locally suppress inflammation by releasing 'keep out' signals such as lactotransferrin or antiinflammatory mediators such as transforming growth factorβ (TGFβ) or programmed cell death 1 ligand 1 (PDL1). By con trast, cell rupture after necroptosis leads to the release of inflammatory damageassociated molecular patterns (DAMPs), which can activate the innate immune sys tem and neighbouring cells via PRRs 53 . Moreover, RIPK3 activation has also been implicated in the activation of the NLRP3 inflammasome [57] [58] [59] . However, in the liver, the distinction between nonreactive apoptosis and highly reactive necroptosis and necrosis does not seem to reflect clinical findings because apoptosis is clearly associated with disease development and often leads to cellular leakage and inflammation. This finding could be due to a number of factors: an insufficient ability of phagocytic cells to clear apoptotic cells in the setting of massive injury, which might lead to secondary necrosis and release of DAMPs 50 ; coexistence of apoptosis with other forms of cell death; or yet unknown features of hepatocyte apoptosis, which might trigger inflammatory signals in phagocytic cells or other cell types in specific settings 3 , possibly to enable hepatocyte regeneration and restoration of liver function following loss of hepatocytes via apoptosis. In CLD that spans years or decades, cell death triggers chronic inflammation, regeneration and a progressive buildup of extracellular matrix (ECM) 3 . These three responses to hepatocyte death are thought to drive disease progression and the development of HCC in CLD (Fig. 3) .
Fibroinflammation
With the activation of fibrogenic cells being concerted by proinflammatory cells and mediators 60 , it seems that cell death largely promotes fibrosis through inflam mation rather than by directly triggering it (Fig. 3) . However, apoptotic bodies 61, 62 and possibly DAMPs (R.F.S., unpublished observations) might directly acti vate fibrogenic cells, thus bypassing inflammatory cells and mediators. Qualitative and quantitative changes in ECM alter epithelial cell behaviour and might activate tumourpromoting pathways, in part through increased stiffness and via mechanosensitive signalling pathways Apoptosis and necroptosis, triggered by chronic liver diseases such as viral hepatitis, nonalcoholic steatohepatitis and alcoholic steatohepatitis, can trigger hepatic regeneration, inflammation and fibrogenesis. Apoptosis is considered a less reactive form of cell death than necroptosis, which is explained by the rapid phagocytosis of apoptotic cells and the caspase 8-mediated inhibition of the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome. However, it seems that apoptotic cells can nonetheless release selective DAMPs or low levels of DAMPs and thereby also trigger inflammation in specific settings (dashed line). Necroptosis on the other hand not only results in increased cellular leakage and damage-associated molecular pattern (DAMP) release but also can contribute to inflammation via receptor-interacting serine/threonine-protein kinase 3 (RIPK3)-mediated NLRP3 inflammasome activation. Chronic regeneration, inflammation and fibrogenesis contribute to progression to cirrhosis and hepatocellular carcinoma (HCC). In specific settings, apoptosis and necroptosis can trigger immunogenic cell death (ICD). ICD requires simultaneous release of DAMPs and antigens or tumour-associated antigens (TAAs) in sufficient amounts and probably inhibits HCC development and might also contribute to antiviral immunity. In the absence of sufficient DAMP and TAA release, tolerogenic cell death (TCD) can occur.
www.nature.com/nrgastro such as the Yesassociated protein (YAP) pathway 63 . Chronic inflammation contributes to not only fibrosis but also epithelial proliferation and survival as well as increased oxidative stress, all of which might promote the development of HCC 64 . The relative potency of apop tosis versus necroptosis to trigger fibrogenesis remains unknown. Although the most popular animal models for liver fibrosis (such as CCl 4 and thioacetamide mod els) are triggered by necrosis, there is a strong correla tion between markers for apoptosis and development of fibrosis in patients 3 .
Regeneration
The nonhierarchical organization of the liver, in which virtually any hepatocyte can serve as a facultative pro genitor or stem cell, endows the liver with a rapid and often lifesaving ability to regenerate, requiring only approximately 1-2 rounds of hepatocyte replication to replenish an entire liver after hepatocyte death or surgi cal loss of liver mass 65 . However, hepatocyte duplication, the predominant form of hepatocyte repopulation in most settings [66] [67] [68] , might pose a higher risk of the accu mulation of cancerpromoting mutations than repopu lation from a hierarchical organization: Stem cells in a hierarchical system are typically lowproliferating, are capable of undergoing asymmetric cell divisions and have low levels of DNA damageinduced metabolites 69, 70 ; these properties mean that cancerpromoting mutations are likely to occur at reduced frequencies. Moreover, mutations occurring in differentiated cells in hierar chical systems are less likely to lead to cancer, as these cells are usually rapidly eliminated by normal turnover. Accordingly, chronic hepatocyte regeneration in CLD triggers replicationinduced DNA damage and predis poses to cancer 71 . Currently, it is not known whether apoptosis and necroptosis activate different regener ative responses. It is conceivable that specific modes of death or low levels of DAMPs might predominantly trigger regeneration from hepatocytes, whereas other modes of cell death or high levels of DAMPs might trig ger regeneration from progenitor cells. The fact that lost hepatocytes need to be replaced regardless of the type of cell death suggests that even nonreactive forms of cell death such as apoptosis must trigger some regenerative responses unless other 'hepatostatsensing' mechanisms detect reduced liver mass independently of cell death.
Immune responses
Cell death can also be immunogenic. This aspect is best demonstrated in the context of cancer chemother apy and radiotherapy, in which the combined release of tumourassociated antigens (TAAs) and DAMPs from dying cells improves antitumour responses [72] [73] [74] , suggesting that the effects of cytostatic and cytotoxic therapies are at least in part mediated through immune mechanisms (Fig. 3) . Although it has been suggested that necroptotic cell death is more reactive and immuno genic than apoptotic cell death, a number of studies have revealed apoptosis as an immunogenic form of cell death in the context of chemotherapy and radiother apy [72] [73] [74] . In contrast to immunogenic cell death induced by cytostatic therapies, cell death in nontransformed and tumour cells is often tolerogenic, probably owing to the lack of TAA release and lower levels of DAMPs 73 . It can be speculated that hepatocyte death promotes immune responses in advanced CLD and contributes to the elimination of malignant cells. 24, 53 . However, DAMPs might also be released following apoptosis, and this effect could be one of the reasons why apoptosis is not always nonreactive. For instance, DAMPs such as highmobility group pro tein B1 (HMGB1) are released from hepatocytes fol lowing stimulation with the FASagonistic antibody Jo2 in vitro 76 or in vivo (R.F.S., unpublished observations) or in the context of chemotherapy or radiotherapy, in which cell death is mostly apoptotic 77 .
Sensing and responding to cell death
HMGB1. This protein is a prototypical DAMP that is released from dying or stressed hepatocytes 78, 79 . HMGB1 is thought to be released only from cells undergoing necrosis or necroptosis, whereas it is firmly bound to DNA in apoptosis because of generalized underacetyl ation of histones 80 . However, high levels of HMGB1 are released from hepatocytes following stimulation with the FAS agonistic antibody Jo2 in vitro 76 or in vivo (R.F.S., unpublished observations), suggesting that HMGB1 is released in the injured liver regardless of cell death mode. Nonetheless, the consequences of HMGB1 mediated cell death seem to differ between apoptotic and necrotic hepatocyte death. Despite HMGB1 release, TNFinduced and FASinduced liver disease did not dif fer between Hmgb1deleted and control mice in regard to the extent of injury, inflammation or survival 79 . By contrast, HMGB1 release had a major effect on ster ile inflammation following necrotic injury induced by acetaminophen or hepatic ischaemia−reperfusion 79 . Mice with hepatocytespecific deletion of Hmgb1 had not only decreased neutrophil recruitment but also reduced injury at late time points, suggesting that HMGB1recruited neutrophils exacerbate injury 79 . In chronic liver injury, the effects of HMGB1 on sterile inflammation are much less pronounced, probably owing to the dominant role of chemokines in neutrophil recruitment 78 . Although some studies have suggested a role for HMGB1 in promoting liver fibrosis 81 , others have shown that HMGB1 has no role in fibrogenesis in a wide range of mouse models and no effect on hepatocyte regeneration following partial hepatectomy or CCl 4 insult 78, 82 . However, HMGB1 has an important function in the progenitor response, with strong decreases seen in hepatocyte progenitor marker expression across five different models 78, 82 . HMGB1 was involved in not only the hepatic progenitor response but also hepatocyte metaplasia and the dedifferentiation of HCC, resulting in reduced tumour burden and more differentiated HCC developing in mice lacking HMGB1 (reF.
78
). Effects of HMGB1 inhibition on HCC were only observed in HCC mouse models with chronic injury and were absent in the purely genotoxic diethylnitrosamine HCC model. Moreover, promoting effects of HMGB1 on progenitor responses were also apparent when HMGB1 was selectively deleted in hepatocytes. Together, these data show that HMGB1, acting as a DAMP and not through a cellautonomous nuclear or intracellular func tion, contributes to the development of acute liver disease and CLD, with most effects in the liver requiring the pres ence of its receptor, receptor for advanced glycosylation end products (RAGE; also known as AGER) 78, 79, 82 . ATP. Injured hepatocytes release ATP, which triggers neutrophil recruitment to the liver but is not required for neutrophil chemotaxis towards injury 83 . ATP stimu lates neutrophil recruitment via its receptor, P2X puri noceptor 7 (P2X7, which is encoded by P2RX7), which promotes subsequent activation of the NLRP3 inflam masome and IL1 production 83 . Accordingly, increased degradation of ATP via apyrase treatment inhibits neutrophil recruitment, whereas genetic deficiency of CD39, an ATPdegrading ectonucleotidase, increases hepatic inflammation and injury in a sepsis model 84 . The role of ATP and P2X7 in acetaminopheninduced liver injury remains controversial. In one study, P2rx7 -/-mice or apyrasetreated mice had decreased liver necro sis, whereas liver injury and mortality were increased in mice lacking CD39 (reF. 85 ). However, in another study, there was no difference in inflammation and injury between P2X7deficient or apyrasetreated mice following acetaminophen treatment 86 .
Formyl peptides. Derived from either bacterial or mito chondrial proteins, formyl peptides are recognized by receptors of the FPR family. FPRs are G proteincoupled chemoattractant receptors with key roles in host defence and inflammation. For example, following heatinduced liver injury, formyl peptide signals from necrotic cells guide neutrophils through nonperfused sinusoids into the injury area 83 . Following acetami nophen overdose in a mouse model, blockade of FPR1 moderately reduced hepatic neutrophil recruitment and liver injury 87 . As one of the main functions of FPRs is the recognition of bacterial ligands, it is not surpris ing that FPRdeficient mice show reduced neutrophil recruitment into the liver after bacterial infections such as those with Listeria monocytogenes 88 .
DNA. The release of DNA from apoptotic hepatocytes and CpG DNA induce the activation of hepatic stellate cells, as determined by measurement of Col1a1 and Tgfb1 mRNA, via binding to TLR9 (reF.
89
). Accordingly, TLR9 deficient mice show reduced liver fibrosis following treatment with CCl 4 (reF.
).
IL-33.
A member of the IL1 family, IL33 is predomi nantly released from necrotic cells. By contrast, in apop totic cells, IL33 is cleaved by proapoptotic caspases, resulting in reduced bioactivity and reduced stability 90, 91 . Thus IL33 is a classical DAMP that is tightly linked to necrosis or necroptosis, and its levels are reduced after knockout of RIPK3 or MLKL but not caspase 8 (reF. 92 ).
IL33 mediates not only skin and lung fibrosis 93, 94 but also liver fibrosis induced by CCl 4 administration, bile duct ligation and Schistosoma mansoni infection [94] [95] [96] . In the liver, IL33 does not mediate fibrosis through dir ect effects on hepatic stellate cells but rather through IL33induced increases in IL13 production in group 2 innate lymphoid cells and subsequent hepatic stellate cell activation 95 . However, the effects of IL33 in the liver seem to be contextdependent, as IL33 deficiency did not ameliorate highfat dietinduced liver fibrosis in a mouse model 97 .
Monosodium urate. Also known as uric acid, mono sodium urate is a DAMP released in the setting of cel lular death 98 . Crystalline monosodium urate, but not soluble uric acid, is a potent inducer of inflammation, which is mediated by activation of the NLRP3 inflam masome 99 . Monosodium urate induces the activation of mouse and human hepatic stellate cells in vitro, as demonstrated by increased expression of COL1A1 and TGFB1 (reF. 100 ). Moreover, mice lacking the NLRP3 inflammasome had reduced liver fibrosis following CCl 4 or thioacetamide treatment 100 .
Detection of apoptosis and necroptosis
Cellular stress and cell death triggered by various patho genic factors are the basis of most if not all acute liver disease and CLDs. Hence, substantial efforts have been made to evaluate which form of cell death underlies specific liver diseases in order to develop not only new biomarkers but also specific therapeutic strategies. At present, apoptosis is the best characterized form of cell death in liver disease. Apoptosis shows clear morpho logical features usually affecting single cells, whereas the classic perception of necrosis normally refers to clusters of parenchymal cells with the morphological features described earlier. Moreover, the mechanisms driving apoptosis are well defined and feature unique aspects. Accordingly, specific histological tests can be applied to detect apoptotic cells in the liver. For instance, the cleav age of caspase 3, which is considered a final and irrevers ible step towards apoptotic cell death, can be detected by specific antibodies that work well in human and mouse liver tissue 71 . Importantly, the TdTmediated dUTP nick end labelling (TUNEL) test, which identifies cells with fragmented DNA, was believed to specifically detect apoptotic cells 101 , but this assumption had to be revised with the discovery of other forms of programmed cell death. Finally, mediators of apoptosis, such as cleavage products of caspases (for example, cytokeratin 18 (CK18; also known as KRT18), which is detected by the mono clonal antibody M30) 102 or soluble FAS and FASL 103 , can be detected in the serum of patients and have been extensively studied for their possible role as prognostic biomarkers in liver disease 104 .
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The discovery of necroptosis put most of these para digms into question because this cell death form shares morphological and biochemical features with both apop tosis and necrosis. As such, necroptosis can be observed as a single cell event 105 but can also affect clusters of parenchymal liver cells 30, 36 . Moreover, necroptosis is mediated by molecules that can also facilitate apoptosis, such as RIPK1. At present, there is no specific test for the immunohistochemical detection of necroptosis (with a similar sensitivity and specificity to that of the available antibodies against cleaved caspase 3 for the detection of apoptosis), which partly explains the many controver sies that still exist on the role of necroptosis in human liver disease. RIPK3 is normally expressed at somewhat low levels in human hepatocytes, but increased expres sion can be induced upon caspase 8 deletion as well as in distinct pathophysiological conditions such as non alcoholic steatohepatitis (NASH) 30, 106 . On the basis of experimental data from cell culture and mouse models, the activation of necroptotic cell death coincides with increased expression of RIPK3 (reF.
30
). However, RIPK3 staining of human livers results in morphologically varying pictures 30, 107 , raising substantial doubts about the specificity of commercially available antibodies for immunohistochemical analyses. By contrast, western blots assessing RIPK3 expression seem to be more spe cific and reliable 106 but do not allow a clear distinction between the activation of this pathway in parenchymal versus nonparenchymal cells.
For some time, the phosphorylation of MLKL was considered a specific and irreversible molecular event driving necroptosis 46 . Hence, an antibody detecting phosphorylated MLKL used to be considered a bona fide tool to specifically detect necroptotic cell death, and interestingly, the use of such an antibody was first documented in human patients with druginduced liver failure 105 . However, in our experience, the com mercially available antibodies work very well in west ern blots in experimental settings that trigger strong activation of MLKL (such as TNF stimulation of L929 osteosarcoma cells), whereas they are not sensitive enough to detect a subtle activation of MLKL in hepato cytes or livers with wildtype caspase 8 (for instance, in mouse NASH models; T.L., unpublished observa tions). Moreover, several papers published in the past year elegantly demonstrated that phosphorylation of MLKL does not necessarily lead to the execution of necroptotic cell death. As such, activated MLKL is part of a molecular process involving vesicle and exosome formation, in collaboration with the endosomal com plexes required for transportIII (ESCRTIII) machin ery 108 . This promotion of phosphorylated MLKL cellular export represents a selfrestriction of activated MLKL and therefore a restriction of necroptosis 109 , illustrating that MLKL phosphorylation by itself is not sufficient to indicate cell death.
On the basis of these data, a combination of bio chemical and morphological tests rather than one single method might be able to provide more solid evidence for the activation of necroptotic cell death in liver dis ease. As such, some authors combined staining meth ods for cleaved caspase 3 with TUNEL -cells staining positive for both caspase 3 and TUNEL were consid ered apoptotic, whereas TUNELpositive cells that were negative for cleaved caspase 3 were considered necro ptotic 110 . However, positive TUNEL staining and nega tive caspase 3 staining might also indicate other forms of nonapoptotic cell death, such as ferroptosis. In another study on the function of endothelial necroptosis in pul monary spreading of tumour cells, the authors combined electron microscopic analyses for ultrastructural signs of necrosis with the detection of Hoechst dye uptake to identify necroptotic cells with leaky membranes in mouse lungs 111 . This approach could be applied to human liver disease, for instance, by using precisioncut liver slices as a tool to viable liver cells ex vivo 112 . Until better detection methods are defined to enable the detec tion of specific cell death forms in vivo with a single test, the interpretation of the contribution of necropto sis or apoptosis in specific liver diseases will rely on a combination of detection methods in human tissues as well as functional data gained in cell culture and murine disease models.
With the exception of a few cell lines that are exceptionally susceptible to necroptosis (such as L929 cells 40 ), the activation of necroptosis in cell culture often requires an additional sensitization step. For instance, sensitization can be achieved by the addition of SMAC mimetic agents (which induce degradation of CIAP proteins, thereby promoting cell death 113 ) or the inhibi tion of apoptosis through chemical inhibitors (such as zVAD 114 ). Caspase 8competent wildtype hepatocytes express RIPK3 at low levels compared with many other cell types 30 . Therefore, primary hepatocytes require several interventional steps to execute necroptosis. By contrast, caspase 8 deletion from hepatocytes is suffi cient to trigger hepatocyte necroptosis and inflamma tion in livers of mice in vivo 30 . This finding supports the notion that the threshold for activation of necroptosis is in general higher in isolated and cultured cells than in vivo, probably owing to cell deathinhibiting cell culture artifacts or the presence of surrounding imm une cells and the availability of potentially important cofactors and cytokines in vivo.
Apoptosis and necroptosis in liver disease
Acute liver injury Soon after the discovery of necroptosis, several studies assessed whether this pathway has a role in experimental models of acute liver injury (Table 1) . Intoxication with acetaminophen is the most clinically relevant cause for druginduced liver injury (DILI) and can be reproduced in wellestablished mouse models 115 . Moreover, the his tological appearance of acetaminopheninduced liver injury suggests the involvement of necrosis rather than apoptosis in this injury model 116 . However, several stud ies came to distinct and conflicting results on the role of necroptosis in acetaminopheninduced liver injury, probably because this pathway was modulated using different technical approaches, such as administration of the small molecule RIPK1 inhibitor necrostatin 1 (Nec1), antisense oligonucleotides against RIPK1 or RIPK3 mRNA or mice with conditional or constitutive knockout of RIPKs [117] [118] [119] [120] [121] . It has become clear that the earlier studies using Nec1 in vivo need to be inter preted with caution, as Nec1 is neither specific for RIPK1 nor stable in vivo 122 . Moreover, two independ ent studies using Ripk3deficient or Mlkldeficient mice in the acetaminophen toxicity model did not reveal any statistically significant difference between wildtype and knockout mice 116, 118 . Several studies suggested that acetaminophenrelated necrosis is not just executed randomly but is influenced by several signalling pathways 123 . In line with this, it should be noted that acetaminophen overdosing causes massive drops in intracellular glutathione levels 115 , a key molecu lar mediator involved in the activation of ferrop tosis 124 . However, the present data clearly suggest that acetaminophenrelated liver injury is not substan tially influenced by the necrosome as the key medi ator of necroptotic cell death. This finding also raises doubts whether necroptosis -previously detected via phosphorylated MLKL staining in patients with acute DILI 105 -is a major contributor to human DILI. Similarly, the role of RIPK1 in acetaminopheninduced liver injury remains poorly understood. Whereas an antisense oligonucleotide approach against RIPK1 ameliorated acetaminopheninduced cell death 118 , this protective function was not confirmed in conditional, hepatocytespecific RIPK1knockout mice 116 . The function of RIPKs in acute liver injury was fur ther investigated in the concanavalin A (ConA) model, 106 161 This table summarizes the current evidence for different cell death forms in specific liver disease aetiologies. The references indicate selected studies supporting or arguing against the detection of apoptosis or necroptosis in human liver disease, their specific relevance in experimental mouse models and positive signals from clinical trials. HCC, hepatocellular carcinoma; IR , ischaemia-reperfusion; MCD, methionine-choline-deficient; MLKL, mixed lineage kinase domain-like protein; NA , not applicable; NASH, nonalcoholic steatohepatitis; ND, no data available; RIPK , receptor-interacting serine/threonine-protein kinase; TAK1, orphan nuclear receptor TAK1; TUNEL , TdT-mediated dUTP nick end labelling.
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which features aspects of an autoimmunerelated injury mechanism dependent on T cells and TNF signal ling 125 . Surprisingly, mice expressing a form of RIPK1 lacking kinase activity were protected in this model, whereas deletion of RIPK1 in hepatocytes aggravated ConAinduced liver injury 126, 127 . Moreover, mice with ablation of RIPK3 were not protected in this model 126 . Together, these findings suggest that in this specific model, RIPKs have an apoptotic signalling role, with RIPK1 possessing a dual proapoptotic and antiapoptotic function. In line with this hypothesis, it was previously shown in mice that the proapoptotic function of RIPK1 in Nemodeficient hepatocytes depends on its kinase function 32 , whereas we identified a kinaseindependent, antiapoptotic scaffolding func tion of RIPK1 in hepatocytes that is mediated through the prevention of proteasomal degradation of the sur vival molecule TRAF2 (reF. 37 ). Ischaemia-reperfusion injury is another form of acute organ injury and has been intensively studied in other organs such as brain 128 , kidney 129 and heart 130 . In the liver, RIPK3 was upregu lated following induction of ischaemia-reperfusion, but the deletion of neither Ripk3 nor Casp8 (which encodes caspase 8) had any protective effect on the degree of liver injury in this model (T.L., unpublished obser vations). This finding argues for noncontrolled, passive necrosis as the major driver of hepatic ischaemia-reperfusion injury, which seems logical in this pathophysiological setting. Taken together, several studies applying a vari ety of experimental interventions came to the conclu sion that necroptosis was involved in the models most commonly used to study acute liver injury in mice (acetaminophen, ConA and ischaemia-reperfusion injury), but studies using genetic models could not con firm a substantial contribution of necroptosis for the acute injury phase in these experimental models. Given the limited evidence for the activation of necroptosis in livers of patients with acute liver injury, we presently do not see a rationale to test necroptosis inhibitors in clinical trials, for instance, in the setting of DILI or autoimmune hepatitis.
Nonalchoholic steatohepatitis and chronic liver disease. Nonalcoholic fatty liver disease (NAFLD) is a serious health problem with rising global incidence 131 . NAFLD -the most common liver disease in the Western world 132 -is typically defined by the presence of steatosis in >5% of hepatocytes in patients with little or no alcohol consumption 133 . NASH defines a more severe form of NAFLD that is characterized by hepatocyte stea tosis, inflammation, hepatocyte cell death and often fibrosis 134 . Theories to explain the molecular and meta bolic alterations driving the initiation and progression of NASH vary between a 'two hit hypothesis' 135 and a 'multiple hit hypothesis' 136 . In these concepts, the first hit constitutes rising hepatic lipid concentrations, which render hepatocytes sensitive to additional hits featuring oxidative stress and hepatocyte cell death that drives inflammation and fibrosis.
In terms of hepatocyte cell death in NASH, most data point towards apoptosis as the key driver. Immuno histochemical tests assessing hepatocyte caspase 3 cleavage and TUNEL test were positive in both liver tis sue from patients with NASH 137 and in commonly used mouse models of NASH 138 . Moreover, noninvasive markers of apoptosis such as circulating CK18 levels are increased in patients with NASH and can predict the presence of the disease 139 . Finally, inhibition of apop tosis using the pancaspase inhibitor VX166 mark edly reduced liver injury and liver fibrosis in db/db mice fed a methionine-cholinedeficient (MCD) diet 140 .
In line with these findings, the oral caspase inhibitor GS9450 -which inhibits caspase 1, caspase 8 and caspase 9 -led to a reduction of alanine aminotrans ferase levels in patients with NASH in a clini cal trial 141 . Other pancaspase inhibitors such as emricasan are currently being tested in large randomized trials in NASH 142 . However, studies have suggested that the role of apoptosis as the only cell death mediator in NASH is overestimated and that necroptosis is a fundamental element in the disease pathogenesis. Necrosis and necroinflammation are typical histological features of NASH 134, 143 , suggesting the involvement of alter native cell death pathways. The initial publication of caspase 3 and caspase 7 cleavage in human NASH showed an immunohistochemical picture of almost 100% caspase 3positive hepatocytes in patients with NASH, compared with no positivity in control cells 137 . However, even in the most severe form of acute liver failure, apoptotic hepatocytes represent a low percent age of all hepa tocytes 144 , probably owing to rapid clear ance. Thus, the specificity of some antibodies against cleaved caspase 3 might not be ideal for immunohisto chemistry in steatotic livers. In our hands, antibodies detecting either activated caspases or RIPK3 expres sion work more specifically in western blot than in immunohistochemical analyses. Using western blot, we could not detect intrahepatic activation of apop tosis in mice fed an MCD diet, whereas RIPK3 was strongly upregulated in this model 106 . More impor tantly, deletion of caspase 3 did not have a strong effect on circulating aminotransferase levels (a surrogate for hepatocytic cell death) in the MCD dietinduced NASH mouse model 138 . Moreover, rather than being protective, ablation of caspase 8 strongly aggravated liver injury and fibrosis in the MCD dietinduced model 106 , suggesting that -in line with its presumed role in development 145 -a primary role of caspase 8 in NASH\ is to prevent hyperactivation of necroptosis. By contrast, inhibition of RIPK3 in the MCD dietinduced NASH model ameliorated liver injury and fibrosis 106 , providing evidence that necroptosis, not apoptosis, is the driver of liver injury and liver fibrosis in this wellestablished mouse model of NASH. Along with these findings in mice, a western blot analysis of frozen liver tissue from a cohort of patients with biopsyproven NASH showed that these patients had lower levels of intrahepatic caspase 3 cleavage than healthy indivi duals. However, patients with NASH had a dramatic upregulation of hepatic RIPK3 expression as an indi cator of necroptosis 106 , suggesting a shift away from apoptotic towards necroptotic signalling in the livers of these patients.
Together, these data provide evidence that, in addi tion to apoptosis, necroptosis is a key regulatory path way in human metabolic liver disease. Therefore, human NASH is one of the few human diseases in which acti vation of necroptosis has been suggested to be active in vivo without the concomitant inhibition of apoptosis. In line with this observation, it is interesting to note that RIPK3knockout mice were also protected in a model of alcoholic liver disease 107 , providing further evidence for a predominant function of necroptosis as a meta bolic cell death pathway in the liver. On the basis of these data, it seems important to revisit whether the efficacy of caspase inhibitors in NASH might be due to inhibition of caspase 1 and inflammasome activation rather than the inhibition of apoptosis. In summary, targeting necroptosis might represent a promising and specific therapeutic approach in human metabolic liver dis ease. However, further preclinical studies are needed to evaluate which parts of the pathway should be pharma cologically inhibited and in which specific cellular com partment their inhibition should be enacted. Of note, inhibition of RIPK3 in a cholinedeficient highfat diet mouse model of NASH resulted in an aggravation of sys temic insulin resistance and increased adipocyte apopto sis 146 , which suggests a compartmentspecific protective function of RIPK3 in fat tissue and argues for hepatocyte specific RIPK3 inhibition, for example via asialoglyco protein receptortargeted silencing approaches as a drug target in patients with NASH. Conversely, targeting of caspase 8 in NASH might be problematic because of its potential to unleash the caspase 8mediated suppression of necroptosis. In addition to blocking the execution of apoptosis or necroptosis through specific inhibitors, one could also envision targeting pathways that con tribute to the activation of apoptosis or necroptosis in NASH. Experimental studies conducted primarily in mouse models that were published in the past few years have suggested that the apoptosis signalregulating kinase 1 (ASK1; also known as MAP3K5)-JNK path way [147] [148] [149] [150] [151] , endoplasmic reticulum stress 152 and the YAP paralogue tafazzin (TAZ) 153 are activated in NASH and that inhibiting ASK1-JNK and TAZ reduces cell death, NASH severity and NASHinduced fibrosis. Likewise, treatment with vitamin E 154 or the farnesoid Xactivated receptor (FXR; also known as NR1H4) agonist obeti cholic acid 155 improved serum alanine aminotransferase levels in patients with NASH. However, only obeticholic acid improved liver fibrosis 154, 155 . Whether these inter ventions primarily affected apoptosis or necroptosis is not known.
Liver cancer
The development of HCC is the final, irreversible step in CLD and the most common cause of death in patients with compensated liver cirrhosis 156 . In turn, cell death is a fundamental driver of hepatocarcinogenesis. Elevated levels of circulating aminotransferases, a surrogate marker of hepatocyte cell death, are highly predictive for the development of liver cancer in patients 157, 158 . Furthermore, there is increasing experimental evidence that programmed cell death pathways are key factors in hepatocarcinogenesis, but their specific functions might vary between the initiation of HCC versus later steps of tumour promotion. In most malignancies, defects in apoptosis are a key step in the malignant transfor mation of cells because apoptosis contributes to safe guarding genomic integrity 159 . Mice with conditional ablation of TAK1 and RIPK3 in parenchymal liver cells (hepatocytes and cholangiocytes) develop specific genetic alterations in these cells that render them insen sitive to apoptotic cell death, which is an essential step of malignant transformation 30 . Moreover, stimulation of apoptosis can be a therapeutic approach in established cancers 159 ; this method was demonstrated in an HCC mouse model using a tumourtargeted TNFrelated apoptosisinducing ligand (TRAIL; also known as TNFSF10) fusion protein 160 . Notably, all common human hepatoma cell lines such as Huh7, HepG2 and Hep3B show a methylationdependent loss of RIPK3 expression and thereby repress the activation of necro ptosis 161 , which suggests that evasion from necroptosis is a similarly important step in the malignant trans formation of HCC. Reestablishment of RIPK3 expres sion by demethylation of its promoter can resensitize tumour cell lines to chemotherapy 161 , suggesting that this approach is an interesting concept to increase the chemosensitivity of HCC, a tumour that normally does not respond to conventional chemotherapy 162 . Although evasion from cell death is a fundamental cellintrinsic step in the process of malignant transfor mation, the induction of cell death is also an important factor that generates a tumourfriendly environment via tumour cellextrinsic mechanisms. In experimen tal mouse models of liver cancer, deletion of a single survival gene such as Nemo or Tak1 from liver cells is sufficient to initiate a fatal sequence of spontaneous hepatocyte apoptosis, immune cell activation, compen satory hepatocyte proliferation, generation of oxidative stress and finally cancer development 29, 31, 106 . Hence, chronic cell death in the liver generates a tumourprone environment from which select hepatocytes, capable of evading cell death, arise and may eventually undergo malignant transformation. This unique relation between cell death and cancer is not seen in any other organ and corresponds with the fact that in human patients liver cancer almost exclusively arises in a chronically dam aged and inflamed liver 4 . A study published in 2017 identified a new apoptosis checkpoint controlled by the molecules RIPK1 and TRAF2 in an experimental mouse model and found that low expression of RIPK1 and TRAF2 in patients with HCC undergoing resection or liver transplantation was predictive of poor prognosis 37 , further corrobo rating the fundamental role of apoptosis in human hepatocarcinogenesis.
The role of necroptosis in the context of hepatocar cinogenesis is less clear. Although clinical evidence for an initiator function of necroptosis in liver cancer does not exist to the best of our knowledge, the role of necrop tosis was studied in the mouse model of Tak1 deletion in parenchymal liver cells. In this model, functional dissection of the specific contributions of apoptosis and necroptosis led to the surprising result that apop tosis strongly promoted cell death responses such as inflammation, compensatory hepatocyte proliferation www.nature.com/nrgastro and carcinogenesis, whereas pure necroptosis activation suppressed inflammation, proliferation and carcino genesis 30 . This unexpected finding is currently not well understood but might be related to the specific molec ular effects of Tak1 deletion on the reactivity of necrop totic cell death responses in the liver. Further studies are therefore needed to define specific DAMP and cytokine signatures that link apoptosis or necroptosis with the progression towards liver cancer. This knowledge could help identify new biomarker signatures to indicate the patients with CLD who are at high risk of develop ing cancer. Moreover, pharmacologically modifying responses to cell death might be a safer strategy when developing chemoprevention strategies than intervening at the level of cell death itself given that the inhibition of one form of cell death increases the risk of activating alternative cell death forms under certain, potentially uncontrollable circumstances.
Targeting apoptosis and necroptosis
Given that cell death has a fundamental role in almost all kinds of liver disease, the number of clinical trials that have assessed or are currently testing the pharma cological modification of cell death pathways in liver disease is somewhat limited. Most clinical trials have tested the inhibition of apoptosis in acute liver disease and CLD on the basis of this cell death form having a more established role in liver disease than necropto sis. Emricasan is a firstinclass pancaspaseinhibitor that was developed for the treatment of liver disease and tested in various preclinical models and clinical trials of hepatic disease 163 . In an initial trial published in 2003, emricasan injected 4 times a day for 7 days was moderately well tolerated and improved liver enzyme levels in patients with elevated circulating aspartate and alanine aminotransferase concentra tions 164 . Since then, emricasan has been tested in several earlyphase clinical trials in distinct indica tions including liver preservation injury after trans plantation 165 , chronic hepatitis C and NASH 166, 167 , and it improved liver enzyme levels in these indications. Current clinical trials are testing the effects of emri casan in patients with NASH fibrosis (NCT02686762), decompensated NASH cirrhosis (NCT03205345) and NASH cirrhosis with severe portal hypertension (NCT02960204), and a study in acuteonchronic liver failure was terminated (NCT02960204). On the basis of the controversial data on the pathophysiological roles of caspase 3 and especially caspase 8 in metabolic liver disease (see earlier discussion) and the implications for targeting them in NASH, it will be interesting to assess how much of the presumably protective func tion of pancaspase inhibitors in human NASH trials stems from the inhibition of caspases such as caspase 1 that are involved in inflammasomerelated signalling, a pathway extremely important in NASH 168 . By con trast, the concept of apoptosis activation for the treat ment of advanced HCC was tested in a phase II trial using a XIAP antisense oligonucleotide (AEG35156) in combination with sorafenib 169 , which yielded a mod erate increase in progressionfree survival (4.0 months versus 2.6 months), overall survival (6.5 months versus 5.4 months) and objective response rate (16.1% versus 9.7%) compared with sorafenib alone.
To our best knowledge, no clinical trials have yet tested the inhibition of necroptosis in liver disease. Given the fairly recent discovery of this pathway and the many open questions regarding the molecular regula tion of necroptosis and its biological function in distinct entities, it is currently not clear which molecule in this pathway is the best candidate to target, how it should be targeted and in which disease a clinical trial should be conducted. In theory, necroptosis can be blocked on multiple levels, for instance, by inhibiting RIPK1, RIPK3 or MLKL. Multiple molecular inhibitors for these mol ecules have been developed and patented, which include: several generations of necrostatins (including Nec1 and Nec2) that inhibit RIPK1; GSKʹ840, GSKʹ843 or GSKʹ872, which inhibit RIPK1 and RIPK3; and the MLKL inhibitor necrosulfonamide 170 . In addition, sev eral natural products and isolated compounds exist with a known inhibitory function on necroptosis, such as curcumin and kongensin A 171, 172 . On the basis of the data summarized above, NASH currently seems to be the liver disease with the highest clinical potential for inhibitors of necroptosis. As no specific NASH therapy has been clinically approved, the potential clinical bene fit and economic incentive for performing a clinical trial in this setting are high. However, data showing a prodiabetic effect of RIPK3 inhibition through pro motion of adipose tissue inflammation in obese mice 146 underline the idea that either hepatocytespecific tar geting of RIPK3, for example via asialoglycoprotein mediated silencing, might be required, or that alternative targets to RIPK3 in the necroptosis pathway need to be tested in NASH to achieve a safe, efficient and specific therapeutic strategy.
Finally, it should be reemphasized that most experimental studies examined cell death forms as independent entities, but their molecular machiner ies and response pathways are strongly interconnected and might be complementary in their effects on the organism, suggesting that targeting multiple cell death pathways will be more efficient than single therapy approaches 173 . On the basis of current experimental evidence, it is possible that combinatorial inhibition of apoptosis and necroptosis in NASH could be an option to increase intervention efficiency and reduce the possible adverse effects of a compensatory acti vation of these pathways following single targeting of either apoptosis or necroptosis. Such an approach would certainly warrant more experimental knowledge of the longterm effects of necroptosis inhibition in humans and more studies in mouse models (for example, in mice lacking both caspase 8 and RIPK3) to ensure that combined inhibition and escape from both pathways would not favour malignant transformation of hepato cytes in chronic inflammation. Also, it is conceivable that targeting pathways that regulate cell death, such as pathways involving ASK1-JNK, FXR, endoplasmic reticulum stress, inflammation and the inflammasome, might prove to be a better approach for NASH and other liver diseases than directly targeting the apoptotic or necroptotic machinery.
Conclusions
The discovery of programmed necrosis represented a paradigmatic change in our understanding of cell death and revitalized a whole field of research in inflammatory diseases. Although it seems that most forms of liver dis ease previously associated with necrotic cell death, such as DILI or ischaemia-reperfusion injury, are not medi ated through necroptosis, increasing evidence suggests that necroptosis contributes to metabolic liver disease and is a promising therapeutic target in NASH and alco holic steatohepatitis. To bridge the gap towards clinical applications, several important questions remain to be resolved experimentally. Further research is needed to define the molecular contexts under which the necrop tosis machinery truly mediates cell death of parenchy mal cells versus just promoting inflammation without killing the cells. Moreover, whereas the mutual inhib itory interaction between apoptosis and necroptosis is well established, further experiments are warranted to explore the interactions of apoptosis or necroptosis with other cell deathrelated pathways, including autophagy, ferroptosis, pyroptosis and others, before targeting them in humans. Of note, most studies on necroptosis in the liver were performed using constitutive RIPK3knockout mice. However, expression levels of RIPK3 in hepato cytes are rather low, suggesting that important functions exist in other cell types including biliary cells, hepatic stellate cells, Kupffer cells or endothelial cells, which could be unravelled by conditional knockout approaches. Finally, there is increasing evidence that distinct cell death forms might be linked with specific inflammatory response patterns. Understanding these patterns of mediators and specifically the DAMPs related to either apoptosis or necroptosis might be valuable for the development of biomarkers indicating the risk of decompensation in CLD. Given the strong interactions between distinct cell death pathways and the risk of activating one form of cell death by modulating another, targeting upstream activators or downstream pathways such as DAMPs or DAMP receptors rather than key components of the cell death machinery represent alternative and possibly safer pharmacological strate gies for the treatment of CLD.
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